Biocon settles Roche's US patent lawsuit over proposed breast-cancer drug copy

By Reuters News

By Blake Brittain

Oct 14 (Reuters) - Roche's ROPC.S Genentech has settled a US lawsuit against Indian biopharmaceutical company Biocon BION.NS over its proposed biosimilar of Genentech's blockbuster breast-cancer drug Perjeta, Biocon said Wednesday.

  • Biocon said in a statement that the settlement gives it the "earliest licensed launch dates" for a Perjeta biosimilar, allowing the company to launch its Pebrilzo in the first quarter of 2027 in the UK and European Union, and the third quarter of 2028 in the United States

  • The release said that other terms of the agreement are confidential

  • Biosimilars are versions of biologic drugs ​that are comparable to generics of traditional pharmaceuticals. Unlike ‌traditional ⁠drugs, complex biologic drugs are made from living cells and cannot be copied exactly

  • Genentech's biologic Perjeta was Switzerland-based Roche's sixth-best-selling ​drug last year, ​earning ⁠it nearly CHF 2.97 billion ($3.67 billion) in revenue worldwide, according to a ​company report

  • Genentech sued Biocon in New Jersey earlier this year, alleging Biocon's biosimilar would infringe its patents

  • The court dismissed the lawsuit on Wednesday at Genentech's request

  • Biocon did not respond to Genentech's allegations in court

The case is Genentech Inc v. Biocon Biologics Inc, US District Court for the District of New Jersey, No. 2:26-cv-09585

For Genentech: Michael Morin of Latham & Watkins

For Biocon: Jeanna Wacker of Kirkland & Ellis

Read more:

Roche sues Biocon over proposed breast-cancer drug copy

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.